炎症性肠病患者应用抗TNF-α单抗发生结核风险的研究进展  

Research progress on the risk of tuberculosis in patients with inflammatory bowel disease treated with anti-TNF-αmonoclonal antibody

作　　者：苏建淋(综述) 廖盛涛 李传飞[1] 吕琳(审校)[1] SU Jianlin;LIAO Shengtao;LI Chuanfei;LV Lin(Department of Gastroenterology,second affiliated Hospital of Chongqing Medical University,Chongqing,400010,China)

机构地区：[1]重庆医科大学附属第二医院消化内科,重庆400010

出　　处：《现代医药卫生》2024年第16期2831-2836,共6页Journal of Modern Medicine & Health

基　　金：重庆市科卫联合医学科研项目(2020GDRC014);重庆市中青年医学高端人才基金项目(11-020);重庆医科大学附属第二医院宽仁英才(骨干人才)基金项目(13-003-023)。

摘　　要：炎症性肠病(IBD)是一种胃肠道慢性非特异性复发性炎症性疾病。抗肿瘤坏死因子-α(TNF-α)单抗的出现极大地改善了IBD患者的预后,但同时也增加了患者发生活动性结核的风险。中国是结核高负担国家,临床医生应高度重视抗TNF-α单抗导致结核的风险。该文回顾了潜伏性结核感染及再激活的机制、抗TNF-α单抗导致结核的风险,以及国内外指南的诊疗推荐,期望能为合并潜伏性结核感染的IBD患者在应用抗TNF-α单抗时提供一些参考依据。Inflammatory bowel disease(IBD)is a chronic non-specific recurrent inflammatory disease of the gastrointestinal tract.The emergence of anti-tumor necrosis factor-α(TNF-α)monoclonal antibody has greatly improved the prognosis of IBD patients,but also increased the risk of active tuberculosis.China is a country with high burden of tuberculosis and clinicians should attach great importance to the risk of tuberculosis caused by anti-TNF-αmonoclonal antibody.This paper reviews the mechanism of latent tuberculosis infection and reactivation,the risk of tuberculosis caused by anti-TNF-αmonoclonal antibody,and the diagnosis and treatment recommendations of domestic and foreign guidelines.It is expected to provide some references for IBD patients with latent tuberculosis infection when using anti-TNF-αmonoclonal antibody.

关 键 词：炎症性肠病 抗TNF-α单抗 结核感染 潜伏性结核筛查 综述 

分 类 号：R574[医药卫生—消化系统] R52[医药卫生—内科学]